Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12292825 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL23419601 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL5326659 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL10078357 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL22061771 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL18536761 | 0.94 | ALDH1A1 (0.88) | ALDH1A1SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL10587847 | 0.91 | ALDH1A1 (0.83) | ALDH1A1SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL6549000 | 0.90 | SMN1; SMN2 (0.84) | ALDH1A1SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL27892098 | 0.90 | ALDH1A1 (0.81) | ALDH1A1SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL10015691 | 0.89 | ALDH1A1 (0.80) | ALDH1A1SMN1; SMN2HPGDEPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11110114-B2 | Dinucleotides | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-09-07 | — | — | US | disclosed |
| US-20210155926-A1 | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS | SILENCE THERAPEUTICS GMBH (DE) | 2021-05-27 | — | — | US | disclosed |
| US-20210147840-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | SILENCE THERAPEUTICS GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20190015439-A1 | DINUCLEOTIDES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11110114-B2 | Dinucleotides | DCLRE1B, NSUN2, POLRMT | ALDH1A1 2716/4885SMN1; SMN2 1335/4885HPGD 1957/4885 |
| US-20190015439-A1 | DINUCLEOTIDES | DCLRE1B, DPYD, NT5C2 | ALDH1A1 2413/4885SMN1; SMN2 2218/4885HPGD 1239/4885 |
| US-20210155926-A1 | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS | NSUN3, SNRPE, RNASE1 | ALDH1A1 2634/4885SMN1; SMN2 2625/4885HPGD 4695/4885 |
| US-20210147840-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | RNASE1, DCLRE1B, SNRPE | ALDH1A1 3841/4885SMN1; SMN2 1806/4885HPGD 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.